Pre-Market Technical Scan on Medical Equipment Equities — Smith & Nephew, Zimmer Biomet, Abbott Labs, and Stryker


NEW YORK, Dec. 29, 2017 strives to bring th–e best free research to the investment community.  Today we are offering reports on SNN, ZBH, ABT, and SYK which can be accessed for free by signing up to On Thursday, December 28, 2017, US markets saw broad based gains with seven out of nine sectors finishing the trading sessions in green. Major US indices were also bullish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,950.16, up 0.16%; the Dow Jones Industrial Average edged 0.26% higher, to finish at 24,837.51; and the S&P 500 closed at 2,687.54, up 0.18%. This Friday morning, looks at the performance of these four Medical Appliances & Equipment stocks: Smith & Nephew PLC (NYSE: SNN), Zimmer Biomet Holdings Inc. (NYSE: ZBH), Abbott Laboratories (NYSE: ABT), and Stryker Corp. (NYSE: SYK). All you have to do is sign up today for this free limited time offer by clicking the link below.

Smith & Nephew

On Thursday, shares in London, the UK headquartered Smith & Nephew PLC recorded a trading volume of 623,184 shares. The stock ended the session 0.37% higher at $35.27. The Company's shares have gained 18.20% in the past twelve months and 17.25% on an YTD basis. The stock is trading above its 200-day moving average by 0.79%. Moreover, shares of the Company, which designs, develops, and sells medical devices worldwide, have a Relative Strength Index (RSI) of 43.74.

On December 11th, 2017, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'. Get the full research report on SNN for free by clicking below at:

Zimmer Biomet Holdings

Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.'s stock closed the day 1.34% higher at $121.75 with a total trading volume of 991,603 shares. The Company's shares have advanced 18.14% over the last twelve months and 17.97% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 5.12% and 2.09%, respectively. Additionally, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, Middle-East, Africa, and Asia/Pacific, have an RSI of 63.56.

On December 20th, 2017, research firm Goldman upgraded the Company's stock rating from 'Sell' to 'Neutral'. Free research on ZBH can be accessed at:

Abbott Laboratories

Shares in North Chicago, Illinois headquartered Abbott Laboratories recorded a trading volume of 3.39 million shares. The stock ended yesterday's trading session 0.02% lower at $57.46. The Company's shares have advanced 50.34% in the past twelve months and 49.60% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 3.47% and 15.24%, respectively. Furthermore, shares of Abbott Labs, which manufactures and sells health care products worldwide, have an RSI of 67.19. Sign up today for the free research report on ABT at:


Kalamazoo, Michigan headquartered Stryker Corp.'s stock finished Thursday's session flat at $155.62 with a total trading volume of 655,703 shares. The Company's shares have advanced 10.98% over the previous three months, 29.81% in the past twelve months, and 29.89% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.13% and 8.45%, respectively. Additionally, shares of Stryker, which together with its subsidiaries, operates as a medical technology company, have an RSI of 56.02. Wall St. Equities' research coverage also includes the downloadable free report on SYK at:

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:—-smith–nephew-zimmer-biomet-abbott-labs-and-stryker-300576015.html

SOURCE Wall St. Equities

Powered by WPeMatico